Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs Haloperidol for Nausea in Advanced Cancer
NCT00124930Phase 3Terminated
- Sponsor
- Alberta Health Services
- Start
- May 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in nausea ((none)) and Vomiting (2 arms), sponsored by Alberta Health Services. Primary endpoint: Severity of nausea at Day 5. Started May 2005; status: terminated.
02
Drugs
olanzapine
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT00124930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124930.